KOMBIGLYZE XR

LOE Approaching

saxagliptin and metformin hydrochloride

NDAORALTABLET, EXTENDED RELEASE
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
37

Mechanism of Action

medications: saxagliptin, a dipeptidyl-peptidase-4 (DPP4) inhibitor, and metformin HCl, a biguanide. Saxagliptin Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from…

Clinical Trials (5)

NCT06099067N/ACompleted

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Started May 2020
239,990 enrolled
Type 2 Diabetes Mellitus
NCT02917031Phase 4Completed

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Started Jan 2017
348 enrolled
Type 2 Diabetes MellitusHeart Failure
NCT02597101Phase 2Completed

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Started Nov 2015
14 enrolled
Type 2 Diabetes MellitusInsulin Resistance
NCT02588859N/ACompleted

Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

Started Oct 2015
1,200 enrolled
Type 2 Diabetes
NCT02273050Phase 3Completed

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Started Dec 2014
1,136 enrolled
Type 2 Diabetes Mellitus